Oxford Asset Management’s BioLineRX BLRX Stock Holding History

Oxford Asset Management’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-38	Closed	-$25K	–	1619
2017 Q4	$25K	Buy	+38	New	+$25K	﹤0.01%	1584

Other funds holding BLRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCA

Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Oxford Asset Management's BLRX Position: Q1 2018 in Review

Oxford Asset Management sold out of BioLineRX (BLRX) in Q1 2018, closing a stake of 38 shares — an estimated $25K sold.

Oxford Asset Management first reported a position in BLRX in Q4 2017 and held it in 1 quarter. The position peaked at $25K in Q4 2017. 28 funds tracked by Wall St. Rank hold BLRX as of Q1 2018.

Oxford Asset Management reported no remaining BioLineRX position as of Q1 2018 after selling out during the quarter.
Oxford Asset Management sold 38 BioLineRX shares in Q1 2018, an estimated $25K.
Oxford Asset Management first reported a position in BioLineRX in Q4 2017 and held it in 1 quarter.
Oxford Asset Management's BioLineRX position peaked at $25K in Q4 2017.
28 funds tracked by Wall St. Rank held BioLineRX as of Q1 2018.

Based on Oxford Asset Management's 13F filing for Q1 2018, filed 15 May 2018.